Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is ...

11, 2025 — Researchers have discovered a new mechanism that is used by a male sex hormone ... Radiation Therapy Reduces Long-Term Side Effects for Patients With Prostate Cancer Nov. 13, 2024 ...

Discover recent research that suggests that precision treatment may improve outcomes in prostate cancer treatment.

Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Radiographic disappearance of metastases could be a surrogate marker for outcomes among patients treated for metastatic ...

Researchers evaluated links between lifestyle and dietary index scores and risk of death in a prospective, multiethnic cohort of men diagnosed with non-metastatic prostate cancer.

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...